Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 64

1.

Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for non-small cell lung cancer: pooled analysis of clinical trials.

Sorich MJ, Rowland A, Karapetis CS, Hopkins AM.

J Thorac Oncol. 2019 Apr 15. pii: S1556-0864(19)30285-0. doi: 10.1016/j.jtho.2019.04.006. [Epub ahead of print]

PMID:
30999110
2.

Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial data.

Hopkins AM, Van Dyk M, Rowland A, Sorich MJ.

Pigment Cell Melanoma Res. 2019 Feb 13. doi: 10.1111/pcmr.12773. [Epub ahead of print]

PMID:
30758912
3.

Use of Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Axitinib Exposure: A Fresh Approach to Precision Dosing in Oncology.

Sorich MJ, Mutlib F, van Dyk M, Hopkins AM, Polasek TM, Marshall JC, Rodrigues AD, Rowland A.

J Clin Pharmacol. 2019 Jun;59(6):872-879. doi: 10.1002/jcph.1377. Epub 2019 Jan 11.

PMID:
30633368
4.

Plasma extracellular nanovesicle (exosome)-derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure.

Rowland A, Ruanglertboon W, van Dyk M, Wijayakumara D, Wood LS, Meech R, Mackenzie PI, Rodrigues AD, Marshall JC, Sorich MJ.

Br J Clin Pharmacol. 2019 Jan;85(1):216-226. doi: 10.1111/bcp.13793. Epub 2018 Nov 16.

PMID:
30340248
5.

Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials.

Hopkins AM, Nguyen AM, Karapetis CS, Rowland A, Sorich MJ.

Cancers (Basel). 2018 Oct 15;10(10). pii: E384. doi: 10.3390/cancers10100384.

6.

Data sharing from pharmaceutical industry sponsored clinical studies: audit of data availability.

Hopkins AM, Rowland A, Sorich MJ.

BMC Med. 2018 Sep 28;16(1):165. doi: 10.1186/s12916-018-1154-z.

7.

Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Drug Exposure.

Rowland A, van Dyk M, Hopkins AM, Mounzer R, Polasek TM, Rostami-Hodjegan A, Sorich MJ.

Clin Pharmacol Ther. 2018 Dec;104(6):1219-1228. doi: 10.1002/cpt.1076. Epub 2018 Apr 19.

PMID:
29574693
8.

Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries.

van Dyk M, Marshall JC, Sorich MJ, Wood LS, Rowland A.

Eur J Clin Pharmacol. 2018 Jul;74(7):913-920. doi: 10.1007/s00228-018-2450-4. Epub 2018 Mar 23.

PMID:
29572563
9.

Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ study.

Mangoni AA, Kichenadasse G, Rowland A, Sorich MJ.

Ther Adv Med Oncol. 2018 Feb 5;10:1758834018755090. doi: 10.1177/1758834018755090. eCollection 2018.

10.

Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.

Polasek TM, Tucker GT, Sorich MJ, Wiese MD, Mohan T, Rostami-Hodjegan A, Korprasertthaworn P, Perera V, Rowland A.

Br J Clin Pharmacol. 2018 Mar;84(3):462-476. doi: 10.1111/bcp.13480. Epub 2018 Jan 11.

11.

Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol.

Rowland A, van Dyk M, Warncken D, Mangoni AA, Sorich MJ, Rowland A.

Br J Clin Pharmacol. 2018 Mar;84(3):501-509. doi: 10.1111/bcp.13478. Epub 2018 Jan 10.

12.

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.

Hopkins AM, Rowland A, Kichenadasse G, Wiese MD, Gurney H, McKinnon RA, Karapetis CS, Sorich MJ.

Br J Cancer. 2017 Sep 26;117(7):913-920. doi: 10.1038/bjc.2017.274. Epub 2017 Aug 24. Review.

13.

Amiodarone-induced thyroid dysfunction and a perturbed N-desethyl-amiodarone to amiodarone ratio: could a drug-induced toxicity be regulating exposure to the offending agent?

Rowland A, Rowland A, Sorich MJ, Mangoni AA.

Eur J Clin Pharmacol. 2017 Aug;73(8):1051-1052. doi: 10.1007/s00228-017-2261-z. Epub 2017 May 3. No abstract available.

PMID:
28470396
14.

The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?

Dias MM, Sorich MJ, Rowland A, Wiese MD, McKinnon RA.

Pharm Res. 2017 Aug;34(8):1544-1550. doi: 10.1007/s11095-017-2128-0. Epub 2017 Feb 24. Review.

PMID:
28236061
15.

Targeted pharmacotherapy after somatic cancer mutation screening.

Polasek TM, Ambler K, Scott HS, Sorich MJ, Kaub PA, Rowland A, Wiese MD, Kichenadasse G.

Version 2. F1000Res. 2016 Jun 30 [revised 2016 Jan 1];5:1551. doi: 10.12688/f1000research.9040.2. eCollection 2016.

16.

Optimized Cocktail Phenotyping Study Protocol Using Physiological Based Pharmacokinetic Modeling and In silico Assessment of Metabolic Drug-Drug Interactions Involving Modafinil.

Rowland A, Mangoni AA, Hopkins A, Sorich MJ, Rowland A.

Front Pharmacol. 2016 Dec 27;7:517. doi: 10.3389/fphar.2016.00517. eCollection 2016.

17.

Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis.

Shahnam A, Ridha Z, Wiese MD, Kichenadasse G, Sorich MJ.

Pharmacogenomics. 2016 Oct;17(15):1725-1732. Epub 2016 Sep 16.

PMID:
27636246
18.

Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.

Rowland A, van Dyk M, Mangoni AA, Miners JO, McKinnon RA, Wiese MD, Rowland A, Kichenadasse G, Gurney H, Sorich MJ.

Expert Opin Drug Metab Toxicol. 2017 Jan;13(1):31-49. Epub 2016 Sep 1. Review.

PMID:
27561659
19.

Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort.

Wabe NT, Sorich MJ, Wechalekar MD, Cleland LG, McWilliams L, Lee AT, Spargo LD, Metcalf RG, Hall C, Proudman SM, Wiese MD.

J Rheumatol. 2016 Sep;43(9):1643-9. doi: 10.3899/jrheum.151392. Epub 2016 Jul 15.

PMID:
27422892
20.

Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.

Sorich MJ, Rowland A, Kichenadasse G, Woodman RJ, Mangoni AA.

Br J Cancer. 2016 Jun 14;114(12):1313-7. doi: 10.1038/bjc.2016.147. Epub 2016 May 26.

Supplemental Content

Loading ...
Support Center